BD Biosciences and Roche Collaborate on Study of Cell Signal Transduction through New Phosphorylation Site Antibody Targets
Under the terms of the agreement, Roche and BD will share information and resources to identify intracellular phosphorylation site target specificities of high interest in a number of disease areas. The two companies will also develop and validate antibodies for those targets using BD Phosflow(TM) technology and in other cell and tissue analysis applications. Roche will receive nonexclusive pre-launch access to all developmental BD Phosflow antibodies and a period of exclusive commercial access to those validated antibodies.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous